File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy

TitleHepatitis B genotypes in chronic hepatitis B and lamivudine therapy
Authors
Issue Date2003
PublisherS Karger AG. The Journal's web site is located at http://www.karger.com/INT
Citation
Intervirology, 2003, v. 46 n. 6, p. 373-376 How to Cite?
AbstractThe influence of hepatitis B virus (HBV) genotypes on the natural history and the response to treatment of patients with chronic hepatitis B are of potential interest. Compared to the patients with HBV genotype C, those with genotype B were of a younger age and had a higher cumulative rate of hepatitis B e antigen (HBeAg) seroconversion during the initial 6 years of follow-up. The earlier HBeAg seroconversion in the patients with genotype B, however, did not provide them with a benefit in terms of a reduced risk of developing long-term complications. The response to lamivudine therapy was evaluated in 21 patients infected with HBV genotype B (all of subtype Ba) and 61 with genotype C. There were no differences in the virological response to lamivudine therapy, based on the reduction in median logarithmic HBV DNA titer as well as alanine aminotransferase (ALT) levels, normalization of ALT and the rate of HBeAg seroconversion between the patients with genotypes B and C. No differences were noted either, in the frequency of YMDD mutants at week 52 or the cumulative risk of HBV DNA breakthroughs with YMDD mutations during long-term lamivudine therapy (median 37.5 months). In conclusion, there is no influence of HBV genotypes on the development of long-term complications and lamivudine therapy in Hong Kong. Copyright © 2003 S. Karger AG, Basel.
Persistent Identifierhttp://hdl.handle.net/10722/76578
ISSN
2015 Impact Factor: 1.822
2015 SCImago Journal Rankings: 0.781
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorTanaka, Yen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-06T07:22:43Z-
dc.date.available2010-09-06T07:22:43Z-
dc.date.issued2003en_HK
dc.identifier.citationIntervirology, 2003, v. 46 n. 6, p. 373-376en_HK
dc.identifier.issn0300-5526en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76578-
dc.description.abstractThe influence of hepatitis B virus (HBV) genotypes on the natural history and the response to treatment of patients with chronic hepatitis B are of potential interest. Compared to the patients with HBV genotype C, those with genotype B were of a younger age and had a higher cumulative rate of hepatitis B e antigen (HBeAg) seroconversion during the initial 6 years of follow-up. The earlier HBeAg seroconversion in the patients with genotype B, however, did not provide them with a benefit in terms of a reduced risk of developing long-term complications. The response to lamivudine therapy was evaluated in 21 patients infected with HBV genotype B (all of subtype Ba) and 61 with genotype C. There were no differences in the virological response to lamivudine therapy, based on the reduction in median logarithmic HBV DNA titer as well as alanine aminotransferase (ALT) levels, normalization of ALT and the rate of HBeAg seroconversion between the patients with genotypes B and C. No differences were noted either, in the frequency of YMDD mutants at week 52 or the cumulative risk of HBV DNA breakthroughs with YMDD mutations during long-term lamivudine therapy (median 37.5 months). In conclusion, there is no influence of HBV genotypes on the development of long-term complications and lamivudine therapy in Hong Kong. Copyright © 2003 S. Karger AG, Basel.en_HK
dc.languageengen_HK
dc.publisherS Karger AG. The Journal's web site is located at http://www.karger.com/INTen_HK
dc.relation.ispartofIntervirologyen_HK
dc.rightsIntervirology. Copyright © S Karger AG.en_HK
dc.subject.meshAdulten_HK
dc.subject.meshAlanine Transaminase - blooden_HK
dc.subject.meshGenotypeen_HK
dc.subject.meshHepatitis B Surface Antigens - analysisen_HK
dc.subject.meshHepatitis B virus - classification - drug effects - geneticsen_HK
dc.subject.meshHepatitis B, Chronic - blood - drug therapy - enzymology - virologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLamivudine - pharmacology - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshReverse Transcriptase Inhibitors - pharmacology - therapeutic useen_HK
dc.titleHepatitis B genotypes in chronic hepatitis B and lamivudine therapyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0300-5526&volume=46&spage=373&epage=376&date=2003&atitle=Hepatitis+B+Genotypes+in+Chronic+Hepatitis+B+And+Lamivudine+Therapyen_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1159/000074995en_HK
dc.identifier.pmid14688455-
dc.identifier.scopuseid_2-s2.0-0346156072en_HK
dc.identifier.hkuros87525en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0346156072&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume46en_HK
dc.identifier.issue6en_HK
dc.identifier.spage373en_HK
dc.identifier.epage376en_HK
dc.identifier.isiWOS:000187454000009-
dc.publisher.placeSwitzerlanden_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridTanaka, Y=7405315865en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats